Drug-induced apoptosis in chronic lymphocytic leukemia

Leukemia

Volumn 13, Issue 11, 1999, Pages 1873-1880

  Stoetzer, O J ^a,b,c   Pogrebniak, A ^b   Scholz, M ^b   Pelka Fleischer, R ^a,b   Gullis, E ^b   Darsow, M ^b   Nussler V ^a,b   Wilmanns, W ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bax; Bcl 2; Caspase 3; CLL; PARP

Indexed keywords

3 AMINOBENZAMIDE; CASPASE 3; CASPASE INHIBITOR; CYTOTOXIC AGENT; DEXAMETHASONE; FLUDARABINE; GLUCOCORTICOID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PREDNISOLONE; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOCYTE; PRIORITY JOURNAL;

EID: 0032745466     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401572     Document Type: Conference Paper

References (63)

1. Caligaris-Cappio F, Gottardi D, Alfarano A, Stacchini A, Gregoretti MG, Ghia P, Bertero M, Novarino A, Bergui L. The nature of B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells 1993; 19: 601-613.
2. Gottardi D, Alfarano AM, De Leo A, Stacchini L, Bergui L, Caligaris-Cappio G. Detective apoptosis due to bcl-2 overexpression may explain why B-C LL cells accumulate in GO. Curr Top Microbiol Immunol 1995; 194: 307-312.
3. Kalvelyte A, Pabrezaite L. Phenomena of spontaneous proliferation, differentiation and apoptosis in primary culture of leukemic lymphocytes. Exp Cell Res, 1994; 211: 344-352.
4. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JFR. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989; 71: 343-350.
5. McConkey DJ, Aguilar-Santelises M, Hartzell P, Eriksson I, Mellstedt H, Orrenius S, Jondal M. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol 1991; 146: 1072-1080.
6. Begletier A, Lee K, Israels LG, Mowat MRA, Johnston JB. Chlorambucil-induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 1994; 8 (Suppl. 1): 103-106.
7. Carrera CJ, Piro LD, Saven A, Beutler E, Rerai C, Carson DA. 2-Chlorodeoyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv Exp Med Biol 1991; 309A: 15-20.
8. Castejon R, Vargas JA, Briz M, Berrocal E, Romero Y, Gea-Banacloche JC, Fernandez MN, Durantez A. Induction of apoptosis by 2-chlorodeosyadenosine in B cell chronic lymphocytic leukemia. Leukemia 1997; 11: 1253-1257.
9. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman N, Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-149.
10. Zinzani PL, Tosi P, Visani G, Martinelli G, Farabegoli P, Buzzi M, Ottaviani E, Salvucci M, Bendandi M, Zaccaria A, Tura S. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47: 301-306.
11. Zinzani PL, Buzzi M, Farabegoli P, Tosi P, Fortuna A, Visani G, Martinelli G, Zaccaria A, Tura S. Induction of in vitro apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells. Leuk Lymphoma 1994; 13: 95-97.
12. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trend Biochem Sci 1997; 22: 299-306.
13. Tewari M, Quan LT, O'Rourke K, Desnoyers Z. Yama/CPP32b, a mammalian homolog of ced-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-809.
14. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 1996; 183: 1957-1964.
15. Miller DK. The role of the caspase family of cyteine proteases in apoptosis. Semin Immunol 1997; 9: 35-49.
16. Nicholson WD, Thornberry NA, Vaillancourt JP. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
17. Thornberry NA, Bull HG, Calayeay JR. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992; 356: 768-774.
18. Alnemri ES, Livingston DJ, Nicholson DW, Thornberry NA, Yuan J. Human ICE/CED-3 protease nomenclature. Cell 1996; 87: 171.
19. Enari M, Talaninian RV, Wong W, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996; 380: 723-726.
20. Mashima T, Noito M, Fujita N, Nogouchi K, Tsuruo T. Identification of actin as a substrate of ICE and an ICE-like protease and involvement of an ICE-like protease but not ICE in VP-16 induced U937 apoptosis. Biochem Biophys Res Commun 1995; 217: 1185-1192.
21. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976-3985.
22. Casciola-Rosen LA, Anhalt GJ, Rosen A. DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 1995; 182: 1625-1634.
23. Casciola-Rolen L, Miller DK, Anhalt GJ, Rosen A. Specific cleavage of the 70-kDA protein component of the U1 small nuclear ribonucleaprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem 1994; 269: 30757-30760.
24. An B, Dou QP. Cleavage of retinoblastoma protein during apoptosis: an inlerleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res 1996; 56: 438-442.
25. Emoto Y, Manome Y, Meinahardt G, Kisaki S, Kharbanda S, Robertson M, Weichselbaum R, Kufe D. Proteolytic activation of protein kinase C δ by and ICE-like protease in apoptotic cells. EMBO J 1995; 14: 6969-6978.
26. Lazebnik YA, Takahashi A, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 1995; 92: 9042-9046.
27. Los M, Van de Craen M, Penning LC, Schenk H, Wenstendorp M, Baeurle PA, Dröge W, Krammer P, Flers W, Schulze-Osthoff K. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 1995; 375: 81-83.
28. Friesen C, Herr I, Krammer PH, Debatim KM. Involvement of the CD95 (APO-1/Fas) receptor/Iigand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
29. Jacobson MD, Weil M, Raff M. Role of CED-3/ICE-family proteases in staurosporine-induced programmed cell death. J Cell Biol 1996; 133: 1041-1051.
30. Bellosillo B, Dalmau M, Colomer D, Gil D. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic cells. Blood 1997; 89: 3378-3384.
31. Althaus FR, Richter C. ADP-ribosylation of protein. Enzymology and biological significance. Mol Biol Biochem Biophys 1987; 37: 231-237.
32. DeMurcia G, Hurletsky A, Poirier GG. Review: modulation of chromatin structure by poly(ADP-ribosyl)ation. Biochem Cell Biol 1988; 66: 626-635.
33. Berger NA, Berger SJ, Sudar DC, Distelhort C. Role of nicotinamide andenine dinucleotide and adenoside triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells. J Clin Invest 1987; 79: 1558-1565.
34. Tanizawa A, Kubota M, Mikawa H. VP-16-induced nucleotide pool changes and poly(ADP-ribose) synthesis; the role of VP-16 in interphase death. Exp Cell Res 1989; 185: 237-246.
35. Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand brakes. TIBS 1995; 20: 405-412.
36. Lazebnik YA, Kaufmann SH, Desnoyers S, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-347.
37. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995; 77: 408-422.
38. Hsu B, Marin MC, Krisbay S, McConnel K, McDonnell TJ. Expression of bcl-2 confers multidrug resistance to chemotherapy induced cell death. Cancer Bull 1994; 46: 125-129.
39. Hockenbery D, Nunez G, Milliman C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
40. Reed J. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
41. Krajewski S, Tanaka S, Takayana S, Schibler MJ, Fenton W, Reed JC. Investigations of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993; 53: 4701-4714.
42. Delia D, Arello A, Soligo D, Fontanella E, Melani C, Pezzalla F, Pierotti M, Della Porta G. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992; 79: 1291-1298.
43. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell 1993; 74: 609-619.
44. Williams GT, Smith C. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-779.
45. Reed JC. Structure-function analysis of bcl-2 family proteins. Adv Exp Med Biol 1996; 406: 99-112.
46. Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T Imphocytes on formalin-fixed and paraffin-embedded tumour sections. Nature Med 1995; 1: 267-271.
47. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
48. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CA. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 1995; 184: 39-51.
49. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, Tsujimoto Y. Involvement of CPP32/Yama(-like) proteasein fasmediated apoptosis. Cancer Res 1996; 56: 1713-1718.
50. Berger NA, Weber G, Kaichi AS. Characterization and comparison of ply(adenosine dephosphoribose) synthesis and DNA synthesis in nucleotide-permeable cells. Biochim Biophys Acta 1978; 519: 87-104.
51. McConkey DJ, Chanra J, Wright S, Plunkett W, McDonnel TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of bcl-2 and bax. J Immunol 1996; 156: 2624-2630.
52. Frankfurt OS, Byrnes JJ, Seckinger D, Sugarbaker EV. Apoptosis and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Oncol Res 1993; 5: 37-42.
53. Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K, Caligaris-Cappio F. Growth-and differentiation-associated expression of bcl-2 in chronic lymphocytic leukemia cells. Blood 1992; 79: 2981-2989.
54. Mariano M, Moretti L, Donelli A, Grantini M, Monatgnani A, DiPrisco A, Torelli U, Narni F. bcl-2 gene expression in hematopoietic cell differentiation. Blood 1992; 80: 768-775.
55. Hanada M, Delia D, Aiello A, Stadtmauere E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820-1828.
56. Thomas A, Rouby SE, Reed IC, Krajewski S, Silber R, Potmesil M, Newcomb EW. Drug induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055-1062.
57. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996; 95: 513-517.
58. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76: 935-938.
59. Begleiter A, Mowat M, Israels LG, Johnston JB. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma 1996; 23: 187-201.
60. Morabito F, Fingeri M, Callea I, Sculli G, Callea V, Francchiolla NS, Neri A, Brugiatelli M. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia; correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 1997; 82: 16-20.
61. Petersen AJ, Brown RD, Gibson J, Pope B, Luo X-F, Wiley JS, Joshua DE. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analgues in vitro. Eur J Haematol 1996; 56: 213-220.
62. Hu ZB, Minden MD, McCulloch EA. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. Leukemia 1996; 10: 410-416.
63. Rosenthal DS, Ding R, Simbulan-Rosenthal CM, Vaillancourt JP, Nicholson DW, Smulson M. Intact cell evidence for the early synthesis, and subsequent late apopain-mediated suppression, of poly(ADP-ribose) during apoptosis. Exp Cell Res 1997; 232: 313-321.